Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study

Clinical Therapeutics

Volumn 29, Issue 7, 2007, Pages 1354-1367

  Davidson, Michael H ^a   Stein, Evan A ^b   Bays, Harold E ^c   Maki, Kevin C ^d   Doyle, Ralph T ^e   Shalwitz, Robert A ^e   Ballantyne, Christie M ^f   Ginsberg, Henry N ^g  

^a RADIANT RESEARCH   (United States)

^b Metabolic and Atherosclerosis Research Center   (United States)

^c LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^d Provident Clinical Research   (United States)

^e Reliant Pharmaceuticals Inc   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g Columbia University ^*  (United States)

Author keywords

combination therapy; dyslipidemia; hypertriglyceridemia; lipoproteins; non HDL C; omega 3 fatty acids; statins

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOVAZA; OMEGA 3 FATTY ACID; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYOPATHY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PATIENT COUNSELING; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RHINOPHARYNGITIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 34548319692     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.07.018     Document Type: Article

References (35)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
2. Davidson M., Maki K., Pearson T., et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
3. Cui Y., Blumenthal R., Flaws J., et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161 (2001) 1413-1419
4. Bittner V., Hardison R., Kelsey S., et al., for the Bypass Angioplasty Revascularization Investigation. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 106 (2002) 2537-2542
5. Ballantyne C., Andrews T., Hsia J., et al., for the ACCESS Study Group (Atorvastatin Comparative Cholesterol Efficacy and Safety Study). Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 88 (2001) 265-269
6. Lovaza (2007), Reliant Pharmaceuticals, Inc, Liberty Corner, NJ [package insert]
7. Nordoy A., Bonaa K., Nilsen H., et al. Effects of simvastatin and omega-3 fatty acids in plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 243 (1998) 163-170
8. Durrington P., Bhatnagar D., Mackness M., et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 85 (2001) 544-548
9. Chan D., Watts G., Mori T., et al. Factorial study of the effects ofatorvastatin and fish oil on dyslipidaemia in visceral obesity. EurJ Clin Invest 32 (2002) 429-436
10. Food and Drug Administration. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance. Available at http://www.fda.gov/cder/guidance/959fnI.pdf. Accessed June 14, 2007.
11. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Available at: http://www.wm a.net/e/policy/b3, htm. Accessed June 15, 2007.
12. Code of Federal Regulations. Title 21--Food and Drugs. Available at: http://www.accessdata, fda.gov/scripts/cdrh/cfdocs/cfCFR/CFR Search.cfm. Accessed June 14, 2007.
13. Fructosamine reagent (1999), Roche Diagnostics Corp, Indianapolis, Ind [package insert]
14. Montgomery D. Design and Analysis of Experiments. 5 (2001), John Wiley & Sons, New York, NY
15. Shapiro S., and Wilk M. An analysis of variance test for normality (complete samples). Biometrika 52 (1965) 591-611
16. Fisher I. On the interpretation of %2 from contingency tables, and the calculation of p. J Royal Star Soc 85 (1922) 87-94
17. Ford E., Giles W., and Dietz W. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
18. Alexander C., Landsman P., Teutsch S., Haffner S., and for the Third National Health and Nutrition Examination Survey (NHANES III) and the National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
19. Assmann G., Schulte H., Funke H., and von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur HeartJ 19 SuppI M (1998) M8-M14
20. McKenney J., Jones P., Adamczyk M., et al., for the STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: Results from the STELLAR trial. Curr Med Res Opin 19 (2003) 689-698
21. Isaacsohn J., Hunninghake D., Schrott H., et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol 26 (2003) 18-24
22. McKenney J., McCormick L., Schaefer E., et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88 (2001) 270-274
23. Austin M., Hokanson J., and Edwards K. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 (1998) 7B-12B
24. Harris W., Ginsberg H., Arunakul N., et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 4 (1997) 385-391
25. Pownall H., Brauchi D., Kilinc C., et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 143 (1999) 285-297
26. Montori V., Farmer A., Wollan P., and Dinneen S. Fish oil supplementation in type 2 diabetes: A quantitative systematic review. Diabetes Care 23 (2000) 1407-1415
27. Balk E., Chung M., Lichtenstein A., et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evidence report/technology assessment no 93. AHRQ publication no 04-E010-2. Rockville, Md: Agency for Healthcare Research and Quality (2004)
28. McKenney J., Swearingen D., DiSpirito M., et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 46 (2006) 785-791
29. Nordoy A., Hansen J., Brox J., and Svensson B. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metal) Cardiovasc Dis 11 (2001) 7-16
30. Yahagi N., Shimano H., Hasty A., et al. A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem 274 (1999) 35840-35844
31. Froyland L., Madsen L., Slursen W., et al. Effect of 3-thia fatty acids on the lipid composition of rat liver, lipoproteins, and heart. J Lipid Res 38 (1997) 1522-1534
32. Dagnelie P., Rietveld T., Swart G., et al. Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies and triacylglycerol in humans. Lipids 29 (1994) 41-45
33. Park Y., and Harris W. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 44 (2003) 455-463
34. Harris W., and Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides?. Curr Opin Lipidol 17 (2006) 387-393
35. Chan D., Watts G., Barrett P., et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 51 (2002) 2377-2386